問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital Yunlin Branch 
National Taiwan University Hospital Yunlin Branch

Division of Neurology

國立臺灣大學醫學院附設醫院雲林分院

Division of Neurology

更新時間：2024-02-21

古宗禾
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

古宗禾

List

5Cases

2025-01-01 - 2031-12-31

Phase III

Active
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    Prefilled Injectable

Participate Sites
12Sites

Recruiting12Sites

2023-05-01 - 2027-06-24

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2024-04-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-02-01 - 2029-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-05-01 - 2027-06-24

Phase III

Active
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

  • Condition/Disease

    Ischemic Stroke; Ischemic Attack, Transient

  • Test Drug

    錠劑

Participate Sites
12Sites

Recruiting12Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB